Loading...
Nivolumab in relapsed/refractory Hodgkin lymphoma: towards a new treatment strategy?
Chemo-refractory Hodgkin lymphoma (HL), especially after failure of high-dose therapy and autologous stem cell transplantation (ASCT), has a very poor prognosis. Nivolumab, an anti-PD-1 monoclonal antibody, demonstrated durable responses and manageable toxicity in a significant proportion of HL pati...
Na minha lista:
| Udgivet i: | Am J Blood Res |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
e-Century Publishing Corporation
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8303013/ https://ncbi.nlm.nih.gov/pubmed/34322289 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|